These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27670779)

  • 1. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
    Skouras VS; Maragkos C; Grapsa D; Syrigos KN
    BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting angiogenesis in squamous non-small cell lung cancer.
    Piperdi B; Merla A; Perez-Soler R
    Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
    Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
    Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
    Villaruz LC; Socinski MA
    Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses.
    Liang W; Wu X; Hong S; Zhang Y; Kang S; Fang W; Qin T; Huang Y; Zhao H; Zhang L
    PLoS One; 2014; 9(10):e109757. PubMed ID: 25329056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumor neovasculature in non-small-cell lung cancer.
    Pallis AG; Syrigos KN
    Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting blood vessels for the treatment of non-small cell lung cancer.
    Amir E; Hughes S; Blackhall F; Thatcher N; Ostoros G; Timar J; Tovari J; Kovacs G; Dome B
    Curr Cancer Drug Targets; 2008 Aug; 8(5):392-403. PubMed ID: 18690845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
    Scagliotti G; Govindan R
    Oncologist; 2010; 15(5):436-46. PubMed ID: 20427383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
    Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
    Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Subramanian J; Morgensztern D; Govindan R
    Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
    Janning M; Loges S
    Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
    Huang Y; Carbone DP
    Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib for the treatment of non-small-cell lung cancer.
    Rashdan S; Hanna N
    Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib in non-small cell lung cancer: from preclinical to approval.
    Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
    Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapy in nonsmall cell lung cancer.
    Gutierrez M; Giaccone G
    Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging angiogenesis inhibitors for non-small cell lung cancer.
    Malapelle U; Rossi A
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
    [No Abstract]   [Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
    Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
    Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.